Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.12 +1.2%	$1.98	$1.60 ▼ $2.54	$815.71M	1.03	1.36 million shs	233,962 shs
EOLS Evolus	$9.57 +0.9%	$9.76	$8.67 ▼ $17.82	$615.91M	0.97	761,582 shs	35,984 shs
GNFT GENFIT	$3.76 +3.0%	$4.10	$2.55 ▼ $6.42	$188M	1.08	10,365 shs	241 shs
NUVB Nuvation Bio	$2.21 +0.2%	$2.14	$1.54 ▼ $3.97	$750.95M	1.33	3.05 million shs	410,895 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	0.00%	+2.45%	+8.29%	+21.51%	-13.28%
EOLS Evolus	0.00%	+2.27%	-4.53%	-7.69%	-19.46%
GNFT GENFIT	0.00%	-4.45%	-10.98%	+5.49%	-14.12%
NUVB Nuvation Bio	0.00%	+5.52%	+27.54%	+8.64%	-36.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	1.5745 of 5 stars	0.0	4.0	0.0	1.5	0.0	2.5
EOLS Evolus	3.9095 of 5 stars	3.5	0.0	3.5	2.5	3.3	0.6
GNFT GENFIT	2.3221 of 5 stars	3.5	5.0	0.0	2.1	0.0	0.0
NUVB Nuvation Bio	3.219 of 5 stars	4.6	0.0	0.0	2.6	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
EOLS Evolus	3.00	Buy	$23.75	148.22% Upside
GNFT GENFIT	3.00	Buy	$13.00	245.74% Upside
NUVB Nuvation Bio	3.20	Buy	$7.17	225.02% Upside

Current Analyst Ratings Breakdown

Latest GNFT, NUVB, CRON, and EOLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
6/17/2025	NUVB Nuvation Bio	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$10.00 ➝ $6.00
6/11/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00
6/2/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $5.00
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/23/2025	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	NUVB Nuvation Bio	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$6.00
4/23/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$6.00
4/17/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	6.94	N/A	N/A	$2.90 per share	0.73
EOLS Evolus	$266.27M	2.32	N/A	N/A	$0.09 per share	106.31
GNFT GENFIT	$76.77M	2.45	$0.07 per share	52.18	$1.50 per share	2.51
NUVB Nuvation Bio	$7.87M	95.33	N/A	N/A	$1.37 per share	1.61

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.13	16.27	70.50	N/A	39.69%	-0.07%	-0.07%	8/6/2025 (Estimated)
EOLS Evolus	-$50.42M	-$0.89	N/A	N/A	N/A	-20.40%	-759.04%	-20.14%	7/30/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
NUVB Nuvation Bio	-$567.94M	-$2.35	N/A	N/A	N/A	-5,534.21%	-44.14%	-32.97%	8/4/2025 (Estimated)

Latest GNFT, NUVB, CRON, and EOLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	NUVB Nuvation Bio	-$0.17	N/A	N/A	N/A	$0.42 million	N/A
7/30/2025	Q2 2025	EOLS Evolus	-$0.09	N/A	N/A	N/A	$82.18 million	N/A
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	27.80	26.75
EOLS Evolus	22.00	2.34	2.16
GNFT GENFIT	0.08	1.23	1.23
NUVB Nuvation Bio	N/A	9.01	9.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
EOLS Evolus	90.69%
GNFT GENFIT	2.24%
NUVB Nuvation Bio	61.67%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	6.90%
EOLS Evolus	6.10%
GNFT GENFIT	4.20%
NUVB Nuvation Bio	29.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.68 million	359.07 million	Optionable
EOLS Evolus	170	64.48 million	60.54 million	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
NUVB Nuvation Bio	60	340.26 million	238.42 million	Optionable

GNFT, NUVB, CRON, and EOLS Headlines

Recent News About These Companies

All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade ... - Nasdaq

July 11 at 6:56 PM | nasdaq.com

Analysts Set Nuvation Bio Inc. (NYSE:NUVB) PT at $7.17

July 10, 2025 | americanbankingnews.com

All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy

July 9, 2025 | zacks.com

Nuvation Bio (NYSE:NUVB) Shares Gap Up - What's Next?

July 9, 2025 | marketbeat.com

Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Buy" from Brokerages

July 7, 2025 | marketbeat.com

Nuvation Bio Inc. (NUVB) latest stock news and headlines - Yahoo Finance

July 2, 2025 | uk.finance.yahoo.com

Nuvation Bio (NYSE:NUVB) Stock Price Up 8% - Time to Buy?

June 30, 2025 | marketbeat.com

JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans

June 29, 2025 | msn.com

Nuvation Bio (NYSE:NUVB) Sees Strong Trading Volume - Here's What Happened

June 25, 2025 | marketbeat.com

Nuvation Bio's (NUVB) "Market Outperform" Rating Reaffirmed at JMP Securities

June 25, 2025 | marketbeat.com

RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating

June 24, 2025 | msn.com

Nuvation Bio jumps after insiders purchase shares worth over $1.1M

June 20, 2025 | msn.com

Nuvation Bio (NYSE:NUVB) Shares Gap Up - Here's Why

June 20, 2025 | marketbeat.com

Founder of Nuvation Bio David Hung Buys More Stock

June 20, 2025 | finance.yahoo.com

Nuvation Bio price target lowered to $6 from $10 at RBC Capital

June 18, 2025 | investing.com

Nuvation Bio: A Justified Fall Based On Post-Marketing Requirements

June 18, 2025 | seekingalpha.com

Royal Bank of Canada Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock Price

June 17, 2025 | marketbeat.com

Nuvation Bio (NYSE:NUVB) Shares Gap Down - Time to Sell?

June 16, 2025 | marketbeat.com

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

June 16, 2025 | globenewswire.com

Nuvation Bio price target maintained at $6 by Citizens JMP

June 14, 2025 | investing.com

Nuvation Bio’s SWOT analysis: FDA approval boosts stock prospects

June 14, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Tech Stocks Poised for Explosive EPS Growth in 2025
By Gabriel Osorio-Mazilli | July 8, 2025
View 3 Tech Stocks Poised for Explosive EPS Growth in 2025
Micron Insiders Sell But Investors Should Buy, Buy, Buy
By Thomas Hughes | July 7, 2025
View Micron Insiders Sell But Investors Should Buy, Buy, Buy
Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming
By Thomas Hughes | June 26, 2025
View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming
Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook
By Leo Miller | July 3, 2025
View Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook
Micron Joins Latest $200 Billion United States Investment
By Gabriel Osorio-Mazilli | June 16, 2025
View Micron Joins Latest $200 Billion United States Investment

GNFT, NUVB, CRON, and EOLS Company Descriptions

Cronos Group NASDAQ:CRON

$2.12 +0.03 (+1.20%)

As of 10:11 AM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Evolus NASDAQ:EOLS

$9.57 +0.09 (+0.93%)

As of 10:12 AM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

GENFIT NASDAQ:GNFT

$3.76 +0.11 (+3.01%)

As of 10:02 AM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Nuvation Bio NYSE:NUVB

$2.20 +0.01 (+0.23%)

As of 10:11 AM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time